Paulo Acosta, MD
Neurology · Nashville, TNNPI 1710097761
Payments from drug & device makers
Across 59 payments — averaging $23.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$260
- Genentech USA, Inc.$137
- Neurelis, Inc.$131
- AstraZeneca$131
- SK Life Science, Inc.$91
- Acadia Pharmaceuticals Inc$89
- plus $526 from 15 others
What the payments were for
- Food & beverage$1,365100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 10 | $260 |
| Genentech USA, Inc. | 5 | $137 |
| Neurelis, Inc. | 8 | $131 |
| AstraZeneca | 5 | $131 |
| SK Life Science, Inc. | 4 | $91 |
| Acadia Pharmaceuticals Inc | 2 | $89 |
| Amgen(2 entities) | 4 | $78 |
| Neurocrine Biosciences, Inc. | 2 | $61 |
| Pfizer | 3 | $57 |
| Lundbeck LLC | 3 | $54 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $54 |
| Catalyst Pharmaceuticals, Inc. | 2 | $31 |
| Teva Pharmaceuticals USA, Inc. | 1 | $31 |
| Biogen | 2 | $29 |
| Amneal Pharmaceuticals LLC | 1 | $26 |
| Medtronic | 1 | $21 |
| EMD Serono, Inc. | 1 | $21 |
| Lilly USA, LLC | 1 | $19 |
| Eisai Inc. | 1 | $17 |
| Otsuka America Pharmaceutical, Inc. | 1 | $15 |
| Zyla Life Sciences, Inc. | 1 | $13 |
How this compares
$1,365 in reported general payments places this provider in the 40th percentile of 361 neurology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Rivastigmine | 29 | $6,480 |
| Levetiracetam | 289 | $5,667 |
| Lacosamide | 26 | $4,129 |
| Donepezil Hcl | 104 | $3,252 |
| Divalproex Sodium ErDivalproex Sodium | 14 | $820 |
| Divalproex Sodium | 39 | $732 |
| Primidone | 13 | $698 |
| Amitriptyline Hcl | 100 | $565 |
| Topiramate | 68 | $499 |
| Memantine Hcl | 33 | $326 |
| Lamotrigine | 14 | $255 |
| Nortriptyline Hcl | 27 | $243 |
| AmantadineAmantadine Hcl | 17 | $205 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 23 | $113 |
Paid to pharmacies, not to this prescriber.
Other neurology in Nashville
- Daniel ClaassenNashville$3.5M
- Siddharama PawateNashville$2M
- John FangNashville$1.5M
- Lealani AcostaNashville$1.4M
- Amy BrownNashville$895K
- Katherine McDonellNashville$862K
- Harold MosesNashville$778K
- Philip CharlesNashville$700K
- Shilpi MittalNashville$481K
- Francesca BagnatoNashville$378K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.